Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR153191 in Ankylosing Spondylitis: randomized double-blind placebo-controlled dose-ranging Phase 2 trial
2009-016068-35Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing SAR153191 with Placebo (2 arms). Primary endpoint: ASAS20 response at Week 12. Started Nov 2009; status: completed.
02
Drugs
sarilumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2009-016068-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016068-35.